S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:SGEN

Seagen (SGEN) Stock Forecast, Price & News

$213.70
+7.31 (+3.54%)
(As of 09/22/2023 ET)
Compare
Today's Range
$213.20
$214.00
50-Day Range
$191.57
$213.70
52-Week Range
$116.08
$214.00
Volume
3.16 million shs
Average Volume
1.35 million shs
Market Capitalization
$40.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$190.47

Seagen MarketRank™ Forecast

Analyst Rating
Hold
2.35 Rating Score
Upside/​Downside
10.9% Downside
$190.47 Price Target
Short Interest
Bearish
3.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.62
Upright™ Environmental Score
News Sentiment
0.83mentions of Seagen in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$4.91 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.40) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

878th out of 968 stocks

Biotechnology Industry

16th out of 22 stocks


SGEN stock logo

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Price History

SGEN Stock News Headlines

Seagen, Activision Blizzard rise; Scholastic, Natural Alternatives fall, Friday, 9/22/2023
Stocks that are trading heavily or have substantial price changes on Friday: Seagen, Activision Blizzard rise; Scholastic, Natural Alternatives fall
Flee to Healthcare Stocks if Recession Rears its Head? (SGEN)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Seagen gains after 'unsuprising' trial result
Why Is Seagen Stock Trading Higher Today?
Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial
Seagen Up In Pre-Market After Positive Results From EV-302 Trial
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Seagen (NASDAQ:SGEN) Coverage Initiated by Analysts at StockNews.com
Investors Buy Large Volume of Seagen Put Options (NASDAQ:SGEN)
Seagen (SGEN) Gets a Hold from BTIG
Seagen Inc Q2 Loss increases, misses estimates
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings
8/02/2023
Today
9/22/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$190.47
High Stock Price Forecast
$229.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
-10.9%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
17 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-32.89%

Debt

Sales & Book Value

Annual Sales
$1.96 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
139,084,000
Market Cap
$40.11 billion
Optionable
Optionable
Beta
0.48

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. David R. Epstein B.Sc. (Age 61)
    M.B.A., CEO & Director
    Comp: $1.39M
  • Mr. Todd E. SimpsonMr. Todd E. Simpson (Age 62)
    Chief Financial Officer
    Comp: $1.26M
  • Dr. Vaughn B. Himes Ph.D. (Age 62)
    Chief Technical Officer
    Comp: $1.08M
  • Ms. Jean I. Liu J.D.Ms. Jean I. Liu J.D. (Age 55)
    M.S., Chief Legal Officer & Corp. Sec.
    Comp: $1.23M
  • Mr. Charles R. RompMr. Charles R. Romp (Age 55)
    Exec. VP of Commercial U.S.
    Comp: $1.08M
  • Dr. Roger D. Dansey M.D. (Age 67)
    Chief Medical Officer and Pres of R&D
    Comp: $2.48M
  • Mr. William Compton
    Sr. VP of Global Information Technology & CIO
  • Mr. David Caouette
    VP of Corp. Communications
  • Mr. Matt Skelton
    VP of Marketing
  • Ms. Peggy M. Pinkston
    Chief HR Officer













SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price forecast for 2023?

17 Wall Street analysts have issued 1-year price objectives for Seagen's shares. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they anticipate the company's stock price to reach $190.47 in the next twelve months. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2023?

Seagen's stock was trading at $128.51 at the beginning of 2023. Since then, SGEN stock has increased by 66.3% and is now trading at $213.70.
View the best growth stocks for 2023 here
.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our SGEN earnings forecast
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.35. The biotechnology company had revenue of $603.83 million for the quarter, compared to analysts' expectations of $555.68 million. Seagen had a negative trailing twelve-month return on equity of 26.46% and a negative net margin of 33.54%.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Capital World Investors (4.84%), Capital International Investors (3.42%), State Street Corp (1.78%), Bluefin Capital Management LLC (0.00%) and Bluefin Capital Management LLC (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $213.70.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $40.11 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis.

How many employees does Seagen have?

The company employs 3,256 workers across the globe.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -